1 published article · Updated continuously
31 trials tracked for Anorexia nervosa: 8 in phase 3 or 4 and 1 with published results. The most-cited published study has 392 citations.
Showing the 31 most-cited and recently-updated of 31 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Pharmacological interventions for anorexia nervosa have shown mixed results regarding physical and psychological outcomes. Fluoxetine was associated with a significant reduction in psychological symptoms as measured by the Beck Anxiety Inventory (p=0.007), though it did not result in a statistically significant change in weight per month (p=0.75) or patient retention at one year (p=0.57) 3. Risperidone showed no significant impact on reaching normal eating behaviors (p=0.55) or improving scores on the Color A Person Test (p=0.47) 4.
Evidence regarding bone health in this population is established through various hormonal and pharmacological agents. Testosterone significantly increased bone mineral density (p<0.0001) and improved markers of bone metabolism (p=0.002) 9. Physiologic estrogen/progesterone also resulted in a significant increase in spine bone density over 18 months (p<0.05) 10. Additionally, Romosozumab showed a significant positive change in lumbar spine bone mineral density at 12 months (p=<0.0001) 5, while Denosumab showed a statistically significant increase in lumbar spine bone mineral density (p=0.009) 6.
AI synthesis of 8 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
